BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 39,000 Shares

Key Points

• BioNTech CEO Ugur Sahin sold 39,000 shares at an average price of $98.99, generating $3.86 million. The transaction was made under a pre-arranged Rule 10b5-1 trading plan, leaving him with 341,209 shares.
• Sahin has conducted a series of stock sales throughout September, selling more than 300,000 shares in total during the transactions listed in the article.
• BioNTech shares traded near $99.26, while the company reported weaker-than-expected quarterly results: a $2.53 loss per share and $122.31 million in revenue, down 59.5% year over year. Analysts nevertheless maintained a “Moderate Buy” consensus with an average price target of $126.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 39,000 shares of the firm's stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $98.99, for a total transaction of $3,860,610.00. Following the transaction, the chief executive officer owned 341,209 shares in the company, valued at $33,776,278.91. This represents a 10.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total transaction of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total value of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total value of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total value of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total transaction of $1,974,355.00.

BioNTech Stock Performance

Shares of NASDAQ BNTX traded up $0.80 during trading hours on Thursday, hitting $99.26. 787,100 shares of the stock were exchanged, compared to its average volume of 1,098,895. The firm has a market capitalization of $25.10 billion, a P/E ratio of -12.68 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00. The company's 50 day moving average is $97.88 and its 200 day moving average is $94.78.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. During the same period in the prior year, the business posted ($1.60) earnings per share. The company's revenue for the quarter was down 59.5% compared to the same quarter last year. On average, research analysts expect that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on BNTX shares. Sanford C. Bernstein reissued a "market perform" rating on shares of BioNTech in a research report on Friday, June 5th. Berenberg Bank set a $140.00 price target on shares of BioNTech in a report on Wednesday, September 16th. Canaccord Genuity Group dropped their price objective on shares of BioNTech from $142.00 to $136.00 and set a "buy" rating on the stock in a report on Monday, August 31st. BMO Capital Markets lowered shares of BioNTech from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $128.00 to $105.00 in a research report on Tuesday, September 8th. Finally, Wall Street Zen cut shares of BioNTech from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, BioNTech presently has an average rating of "Moderate Buy" and an average target price of $126.00.

Institutional Trading of BioNTech

Several institutional investors have recently bought and sold shares of the stock. Larson Financial Group LLC lifted its holdings in shares of BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company's stock valued at $26,000 after acquiring an additional 127 shares during the period. Integrated Wealth Concepts LLC bought a new position in BioNTech during the 2nd quarter valued at about $39,000. Caitong International Asset Management Co. Ltd boosted its position in BioNTech by 1,012.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company's stock valued at $53,000 after buying an additional 506 shares in the last quarter. Vestcor Inc bought a new stake in BioNTech during the fourth quarter worth about $153,000. Finally, Rockefeller Capital Management L.P. increased its holdings in shares of BioNTech by 328.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company's stock worth $177,000 after buying an additional 1,423 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.